A detailed history of Natixis transactions in Catalent, Inc. stock. As of the latest transaction made, Natixis holds 1,537,787 shares of CTLT stock, worth $90.6 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares
1,537,787
Previous 266,292 477.48%
Holding current value
$90.6 Million
Previous $15 Million 522.07%
% of portfolio
0.53%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$56.16 - $60.96 $71.4 Million - $77.5 Million
1,271,495 Added 477.48%
1,537,787 $93.1 Million
Q2 2024

Aug 13, 2024

BUY
$53.58 - $57.02 $960,260 - $1.02 Million
17,922 Added 7.22%
266,292 $15 Million
Q1 2024

May 13, 2024

SELL
$42.56 - $59.82 $170,495 - $239,638
-4,006 Reduced 1.59%
248,370 $14 Million
Q4 2023

Feb 13, 2024

BUY
$32.18 - $46.57 $7.78 Million - $11.3 Million
241,616 Added 2245.5%
252,376 $11.3 Million
Q3 2023

Nov 14, 2023

SELL
$44.2 - $50.2 $8 Million - $9.08 Million
-180,914 Reduced 94.39%
10,760 $489,000
Q2 2023

Aug 11, 2023

BUY
$31.86 - $67.26 $6.11 Million - $12.9 Million
191,674 New
191,674 $8.31 Million
Q4 2022

Feb 13, 2023

BUY
$41.39 - $81.0 $289,730 - $567,000
7,000 Added 21.7%
39,256 $1.77 Million
Q3 2022

Nov 14, 2022

BUY
$72.36 - $113.1 $225,184 - $351,967
3,112 Added 10.68%
32,256 $2.34 Million
Q2 2022

Aug 12, 2022

SELL
$87.2 - $114.05 $675,102 - $882,975
-7,742 Reduced 20.99%
29,144 $3.13 Million
Q1 2022

May 13, 2022

BUY
$94.19 - $124.49 $3.2 Million - $4.23 Million
33,993 Added 1175.01%
36,886 $4.09 Million
Q4 2021

Feb 14, 2022

SELL
$119.57 - $139.07 $337,306 - $392,316
-2,821 Reduced 49.37%
2,893 $371,000
Q3 2021

Nov 12, 2021

SELL
$109.17 - $142.35 $85,916 - $112,029
-787 Reduced 12.11%
5,714 $760,000
Q2 2021

Aug 13, 2021

SELL
$100.34 - $115.69 $1.11 Million - $1.28 Million
-11,069 Reduced 63.0%
6,501 $703,000
Q1 2021

May 14, 2021

SELL
$101.51 - $125.27 $1.96 Million - $2.41 Million
-19,275 Reduced 52.31%
17,570 $1.85 Million
Q4 2020

Feb 12, 2021

BUY
$85.88 - $105.36 $498,104 - $611,088
5,800 Added 18.68%
36,845 $3.83 Million
Q3 2020

Nov 12, 2020

BUY
$72.74 - $92.5 $934,272 - $1.19 Million
12,844 Added 70.57%
31,045 $2.66 Million
Q2 2020

Aug 13, 2020

BUY
$48.02 - $79.04 $874,012 - $1.44 Million
18,201 New
18,201 $1.33 Million
Q2 2019

Aug 13, 2019

SELL
$39.26 - $54.21 $1.17 Million - $1.61 Million
-29,751 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$29.84 - $43.92 $35,987 - $52,967
-1,206 Reduced 3.9%
29,751 $1.21 Million
Q4 2018

Feb 14, 2019

SELL
$29.95 - $46.34 $390,637 - $604,412
-13,043 Reduced 29.64%
30,957 $965,000
Q3 2018

Nov 14, 2018

SELL
$40.12 - $45.55 $348,081 - $395,191
-8,676 Reduced 16.47%
44,000 $2 Million
Q2 2018

Aug 14, 2018

SELL
$38.72 - $42.52 $6.02 Million - $6.61 Million
-155,391 Reduced 74.68%
52,676 $2.21 Million
Q1 2018

May 15, 2018

BUY
$39.4 - $47.39 $813,925 - $978,982
20,658 Added 11.02%
208,067 $8.54 Million
Q4 2017

Feb 14, 2018

BUY
$37.27 - $43.02 $3.58 Million - $4.13 Million
96,019 Added 105.07%
187,409 $7.7 Million
Q3 2017

Nov 14, 2017

BUY
$33.75 - $41.67 $1.61 Million - $1.98 Million
47,562 Added 108.52%
91,390 $3.65 Million
Q2 2017

Aug 14, 2017

BUY
N/A
43,828
43,828 $1.54 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $10.6B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.